Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
NPB
$17.3
$-0.095
Northpointe Bancshares, Inc. operates as the bank holding company for Northpointe Bank provides various banking products and services in the United States. It operates through two segments: Mortgage Purchase Program and Retail Banking. The company offers digital deposit banking, such as noninterest-bearing accounts, savings, money-market demand accounts, and certificates of deposits; personal and business banking; and health saving accounts; home loans; mortgage purchase program; residential mortgage lending; and custodial deposit services. Northpointe Bancshares, Inc. was incorporated in 1998 and is headquartered in Grand Rapids, Michigan.
Next Earnings
2026-01-11
Beta
0.005672214
Average Volume
257012
Market Cap
258481999
Last Dividend
0.075
CIK
0001336706
ISIN
US66661N8864
CUSIP
CEO
Charles A. Williams
Sector
Financial Services
Industry
Banks - Regional
Full Time Employees
491
IPO Date
2025-02-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Northpointe Bancshares, Inc. Declares Quarterly Cash Dividend on Common Stock | GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Dividend--Northpointe Bancshares, Inc. Declares Quarterly Cash Dividend on Common Stock. | Business Wire | 2026-01-06 16:15:00 |
| Northpointe Bancshares, Inc. Announces Date of Fourth Quarter 2025 Earnings Release and Conference Call | GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Earnings--Northpointe Bancshares, Inc. Announces Date of Fourth Quarter 2025 Earnings Release. | Business Wire | 2025-12-19 14:00:00 |
| Northpointe Bancshares, Inc. Announces Completion of $70 Million Subordinated Notes Offering | GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #NPB--Northpointe Bancshares, Inc. Announces Completion of $70 Million Subordinated Notes Offering. | Business Wire | 2025-12-09 16:30:00 |
| 3 Savings & Loan Industry Stocks to Buy on Solid Industry Prospects | NPB, WTBA and CZWI within the Zacks Savings & Loan Industry will gain relatively lower interest rates. Also, digital upgrades will improve operating efficiency. | Zacks Investment Research | 2025-12-01 13:26:05 |
| Financial Contrast: Northpointe Bancshares (NYSE:NPB) versus Timberland Bancorp (NASDAQ:TSBK) | Timberland Bancorp (NASDAQ: TSBK - Get Free Report) and Northpointe Bancshares (NYSE: NPB - Get Free Report) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability. Earnings and Valuation This table compares Timberland | Defense World | 2025-11-17 04:32:50 |
| I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform | New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME Company core asset, givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, continues to advance under previously announced investment plans ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences. | GlobeNewsWire | 2025-10-29 09:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB | NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2025-10-28 10:00:00 |
| Northpointe Bancshares: The Valuation Has Become More Compelling | Northpointe Bancshares is upgraded to Buy, reflecting strong earnings growth and an attractive valuation after initial caution post-IPO. NPB's Mortgage Purchase Program drove a 65% annualized increase in value, while its deposit base has grown 35% in the last 12 months. Despite heavy mortgage exposure and sector risks, NPB's forward P/E of 7.7 and price below book value present compelling value versus peers. | Seeking Alpha | 2025-10-27 08:39:08 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB | NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2025-10-23 10:00:00 |
| I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 | ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated patients (n=45) with gastroesophageal carcinoma (GEC) will be presented as a “short-talk” at the Triple Meeting on October 23, 2025 in Boston, Massachusetts (Presentation #B016). Givastomig is a bispecific antibody targeting CLDN18.2 (Claudin 18.2) and 4-1BB. | GlobeNewsWire | 2025-10-22 12:35:00 |
| Northpointe Bancshares, Inc. (NPB) Q3 2025 Earnings Call Transcript | Northpointe Bancshares, Inc. (NYSE:NPB ) Q3 2025 Earnings Call October 22, 2025 10:00 AM EDT Company Participants Bradley Howes - Executive VP & CFO Charles Williams - Founder, Chairman & CEO Kevin Comps - President & Secretary Conference Call Participants Crispin Love - Piper Sandler & Co., Research Division Damon Del Monte - Keefe, Bruyette, & Woods, Inc., Research Division Presentation Operator Greetings. Welcome to Northpointe Bancshares, Inc. Third Quarter 2025 Earnings Call. | Seeking Alpha | 2025-10-22 12:33:50 |
| Northpointe Bancshares, Inc. Reports Third Quarter 2025 Results | GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Earnings--Northpointe Bancshares, Inc. Reports Third Quarter 2025 Results. | Business Wire | 2025-10-21 17:00:00 |
| I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript | I-Mab (NASDAQ:IMAB ) Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDT Company Participants Xi-Yong Fu - CEO & Director Wei Fu - Executive Chairman Emmett T. Cunningham Kyler Lei Conference Call Participants PJ Kelleher Daina Graybosch - Leerink Partners LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Presentation Operator Good day, and welcome to the I-Mab Business Update Call. | Seeking Alpha | 2025-10-17 18:16:51 |
| I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, announced its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enable broad strategic growth. The Company announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. | GlobeNewsWire | 2025-10-16 16:05:00 |
| I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference | The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md. , Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U. S. -based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesophageal carcinoma (GEC) has been accepted as a "short-talk" at the AACR-NCI-EORTC conference which will be held October 22-26 in Boston, Massachusetts. | GlobeNewsWire | 2025-10-14 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2025-12-31 | 2025-12-31 | View Filing |
| D | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| 6-K | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 6-K | 2025-12-10 | 2025-12-10 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| 6-K | 2025-12-04 | 2025-12-04 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 6-K | 2025-10-31 | 2025-10-31 | View Filing |
| 6-K | 2025-10-30 | 2025-10-29 | View Filing |
| 424B3 | 2025-10-30 | 2025-10-29 | View Filing |
| 4 | 2025-10-29 | 2025-10-29 | View Filing |
| 3 | 2025-10-29 | 2025-10-29 | View Filing |
| 3 | 2025-10-29 | 2025-10-29 | View Filing |
| 3 | 2025-10-29 | 2025-10-29 | View Filing |
| 6-K | 2025-10-29 | 2025-10-29 | View Filing |
| 6-K | 2025-10-28 | 2025-10-28 | View Filing |
| 6-K | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K/A | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K | 2025-10-23 | 2025-10-23 | View Filing |
| 6-K | 2025-10-22 | 2025-10-22 | View Filing |
| 8-K | 2025-10-21 | 2025-10-21 | View Filing |
| SC 13G/A | 2025-10-17 | 2025-10-17 | View Filing |
| 6-K | 2025-10-16 | 2025-10-16 | View Filing |
| 6-K | 2025-10-06 | 2025-10-06 | View Filing |
| 6-K | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-19 | 2025-09-19 | View Filing |
| S-8 | 2025-09-11 | 2025-09-11 | View Filing |
| 6-K | 2025-09-08 | 2025-09-08 | View Filing |
| 6-K | 2025-08-25 | 2025-08-25 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 6-K | 2025-08-11 | 2025-08-11 | View Filing |
| SC 13D/A | 2025-08-07 | 2025-08-07 | View Filing |
| SC 13D | 2025-08-05 | 2025-08-05 | View Filing |
| 424B5 | 2025-08-04 | 2025-08-04 | View Filing |
| 6-K | 2025-08-04 | 2025-08-04 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| F-6EF | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-24 | 2025-07-24 | View Filing |
| 8-K | 2025-07-22 | 2025-07-22 | View Filing |
| 6-K | 2025-07-17 | 2025-07-17 | View Filing |
| 6-K | 2025-07-11 | 2025-07-11 | View Filing |
| 424B5 | 2025-07-11 | 2025-07-11 | View Filing |
| 6-K/A | 2025-07-11 | 2025-07-11 | View Filing |
| 6-K | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 6-K | 2025-06-26 | 2025-06-26 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 6-K | 2025-06-12 | 2025-06-12 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| EFFECT | 2025-05-16 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| 6-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| ARS | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G/A | 2025-05-07 | 2025-05-07 | View Filing |
| SC 13G | 2025-05-07 | 2025-05-07 | View Filing |
| F-3 | 2025-05-02 | 2025-05-02 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-22 | 2025-04-22 | View Filing |
| DEF 14A | 2025-04-11 | 2025-04-11 | View Filing |
| 8-K | 2025-04-08 | 2025-04-08 | View Filing |
| 6-K | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 6-K | 2025-04-03 | 2025-04-03 | View Filing |
| 20-F | 2025-04-03 | 2025-04-03 | View Filing |
| 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 6-K | 2025-03-21 | 2025-03-21 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 6-K | 2025-02-27 | 2025-02-27 | View Filing |
| SC 13G | 2025-02-24 | 2025-02-24 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 3 | 2025-02-21 | 2025-02-21 | View Filing |
| 3 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 3 | 2025-02-19 | 2025-02-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 12.78% | 1 | 671 | 0.02 | 0.05 | 10.69 |
| Williams PercentR Strategy | 8.55% | 1.01 | 286 | 0.02 | 0.07 | 6.46 |
| Volatility Squeeze | 7.63% | 0.99 | 46 | 0.03 | 0.09 | 5.54 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | x |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |